Has Danny Markabawi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,152 in general payments to Danny Markabawi, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danny Markabawi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danny Markabawi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danny Markabawi, MD

Hematology & Oncology · Camden, NJNPI 1124472972

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 24.0% of the total. Reporting peaked in 2021 at $520 and has fallen 86.7% since, to $69 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.

$1,152in general payments, 2019–2025

Across 16 payments — averaging $72.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$277
E.r. Squibb & Sons, L.L.C.$228
Incyte Corporation$140
Genentech USA, Inc.$115
Jazz Pharmaceuticals Inc.$95
Dendreon Pharmaceuticals LLC$81
plus $217 from 6 others

$130,425in research payments, 2019–2025

Across 2 payments — averaging $65,213 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$130K

What the payments were for

Food & beverage$1,152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	3	$277
E.r. Squibb & Sons, L.L.C.	2	$228
Incyte Corporation	1	$140
Genentech USA, Inc.	1	$115
Jazz Pharmaceuticals Inc.	1	$95
Dendreon Pharmaceuticals LLC	1	$81
Astellas Pharma US Inc	1	$74
Merck	2	$55
Eisai Inc.	1	$34
Seagen Inc.	1	$19
Daiichi Sankyo Inc.	1	$19
Caris MPI, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

JAKAFI$140
TAGRISSO$128
Enhertu$125
OPDIVO$125
Alecensa$115
TECENTRIQ$115
ELIQUIS$103

How this compares

$1,152 in reported general payments places this provider in the 35th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$51,036

Medicare patients

209

Services billed

523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VerzenioAbemaciclib	18	$257,466
EliquisApixaban	82	$56,886
Abiraterone Acetate	11	$18,479
Exemestane	63	$14,564
Letrozole	182	$4,463
Enoxaparin Sodium	17	$3,054
Anastrozole	73	$2,042
Raloxifene Hcl	13	$1,501
Tamoxifen Citrate	21	$654
Hydroxyurea	17	$484
Duloxetine Hcl	20	$423
Prochlorperazine Maleate	22	$409
Ondansetron OdtOndansetron	35	$381
Dexamethasone	17	$367
Lidocaine-PrilocaineLidocaine/Prilocaine	19	$176

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Camden

Peter GeorgesCamden$91K
Ahmed Abou HusseinCamden$87K
Rabia CattieCamden$42K
Michael RachshtutCamden$35K
Generosa GranaCamden$34K
Pallav MehtaCamden$22K
Robert SpiegelWestfield$864K
Amit PatelJersey City$770K
Joshua StraussSpringfield$739K
Charles FarberMorristown$609K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →